Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 3
2013 3
2014 4
2015 4
2016 1
2017 1
2018 1
2021 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma.
Gonzalez-Montes Y, Rodriguez-Romanos R, Villavicencio A, Osca-Gelis G, González-Bártulos M, Llopis F, Clapes V, Oriol A, Sureda A, Escoda L, Sarrà J, Garzó A, Lloveras N, Díez I, Granada I, Gallardo D. Gonzalez-Montes Y, et al. Among authors: osca gelis g. Front Immunol. 2023 Apr 12;14:1158105. doi: 10.3389/fimmu.2023.1158105. eCollection 2023. Front Immunol. 2023. PMID: 37122695 Free PMC article.
CD200 genotype is associated with clinical outcome of patients with multiple myeloma.
Gonzalez-Montes Y, Osca-Gelis G, Rodriguez-Romanos R, Villavicencio A, González-Bártulos M, Llopis F, Clapes V, Oriol A, Sureda A, Escoda L, Sarrà J, Garzó A, Lloveras N, Gómez B, Granada I, Gallardo D. Gonzalez-Montes Y, et al. Among authors: osca gelis g. Front Immunol. 2024 Feb 22;15:1252445. doi: 10.3389/fimmu.2024.1252445. eCollection 2024. Front Immunol. 2024. PMID: 38455039 Free PMC article.
Population-based analysis of the prevalence of BRAF mutation in patients diagnosed with cutaneous melanoma and its significance as a prognostic factor.
Rubió-Casadevall J, Carbó-Bagué A, Puigdemont M, Osca-Gelis G, Oliveras G, Vilar-Coromina N, Ferrer-Fabrega B, Urban A, Llobet-Roma M, Martín-Romero F, Perez-Bueno F, Marcos-Gragera R. Rubió-Casadevall J, et al. Among authors: osca gelis g. Eur J Dermatol. 2021 Oct 1;31(5):616-622. doi: 10.1684/ejd.2021.4136. Eur J Dermatol. 2021. PMID: 34789445
Effect of mismatching for mHA UTA2-1 on clinical outcome after HLA-identical sibling donor allo-SCT.
Bosch-Vizcaya A, Rodriguez-Romanos R, Nieto JB, de la Cámara R, Brunet S, Vallejo C, Osca-Gelis G, Martínez-Laperche C, Buño I, Urbano-Ispizúa Á, González M, Jiménez-Velasco A, Gallardo D. Bosch-Vizcaya A, et al. Among authors: osca gelis g. Bone Marrow Transplant. 2015 Feb;50(2):298-300. doi: 10.1038/bmt.2014.234. Epub 2014 Oct 20. Bone Marrow Transplant. 2015. PMID: 25330223 No abstract available.
Incidence, survival and prevalence of myeloid malignancies in Europe.
Visser O, Trama A, Maynadié M, Stiller C, Marcos-Gragera R, De Angelis R, Mallone S, Tereanu C, Allemani C, Ricardi U, Schouten HC; RARECARE Working Group. Visser O, et al. Eur J Cancer. 2012 Nov;48(17):3257-66. doi: 10.1016/j.ejca.2012.05.024. Epub 2012 Jul 4. Eur J Cancer. 2012. PMID: 22770878
18 results